[Middle East] Key Regulatory Updates on ZOPIJUB, Counterfeit & Real Estate

July 20
1 min

Episode Description

This podcast episode explores important regulatory updates affecting pharmaceuticals, sanctions, and municipal real estate in the Middle East.

The Emirates Medicines Agency in the UAE has initiated a voluntary recall of two batches of ZOPIJUB tablets, mandating healthcare providers to withdraw these immediately. Additionally, the Dubai Health Authority issued Administrative Circular 30/2026 warning against counterfeit batches of DARZALEX®, underscoring compliance obligations.

In Saudi Arabia, new rules approved by the Ministry of Municipal and Rural Affairs and Housing enable early renewal of investment lease contracts, allowing investors to extend leases after half the term has passed, balancing development needs with municipal control.

For more information, visit the Carver Agents website.

Articles mentioned:

  1. ZOPIJUB السحب الطوعي للتشغيلتين من المنتج الطبي
  2. DARZALEX® (daratumumab) تعميم اداري رقم (30/2026) تحذير من استخدام تشغيلات مزيفة من المنتج الطبي
  3. Iran-related Designations; Iran-related and Counter Terrorism Designation Update; Issuance of Iran-related General License
  1. وزارة البلديات والإسكان تعتمد ضوابط التمديد المبكر للعقود الإيجارية للمشاريع الاستثمارية
See all episodes